Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Shopify Eyes 18% Upside After Sharp 2026 Selloff

View original at finance.yahoo.com
“Free cash flow came in at $715 million with a 19% margin.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bulls see potential for stock to reach $183 and higher based on compounding growth across multiple vectors

    60% confidence

  • AI commerce tools including Catalog, Sidekick, and Universal Commerce Protocol could meaningfully lift merchant attach rates over two to three years

    60% confidence

  • Shopify shares have 17.68% upside potential with price target of $132.25 from current price of $112.38

    60% confidence

  • Recommendation is BUY with 90% confidence level

    60% confidence

  • The 38% discount to 52-week high presents opportunity given intact operational momentum and early-stage monetization potential in AI commerce tools and cross-border expansion

    60% confidence

Data points we hold from this source

Shopify Inc. · one month return-13.13 percent
Shopify Inc. · ytd return-30.19 percent
Shopify Inc. · price target132.25 USD
Shopify Inc. · operating income growth35.7 percent
Shopify Inc. · country presence175 countries
Shopify Inc. · free cash flow margin19 percent
Shopify Inc. · b2b gmv growth96 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com